Revenue Performance - Revenue for Q1 Fiscal 2026 was $5.3 billion, an increase of 1.6% as reported and 0.4% on a foreign currency-neutral basis[4] - Medical Essentials segment revenue was $1.6 billion, a 0.6% increase, while Connected Care segment revenue grew by 5.5% to $1.1 billion[9] - International revenue was $2.1 billion, showing a slight increase of 0.2% but a decrease of 2.8% on a foreign currency-neutral basis[8] - Revenues for Q4 2025 were $5,252 million, a 1.6% increase from $5,168 million in Q4 2024[23] - Total revenues for the three months ended December 31, 2025, were $5,252 million, representing a 1.6% increase compared to $5,168 million in the same period of 2024[32] - New BD revenues, excluding the Life Sciences segment, were $4,486 million for the three months ended December 31, 2025, reflecting a 3.5% increase from $4,333 million in 2024[35] Earnings and Profitability - GAAP diluted EPS was $1.34, representing a 28.8% increase compared to the previous year, while adjusted diluted EPS was $2.91, a decrease of 15.2%[7] - Operating income rose to $552 million, reflecting a 21.8% increase compared to $453 million in the previous year[23] - Net income increased by 26.1% to $382 million from $303 million year-over-year[23] - Basic earnings per share (EPS) improved by 27.6% to $1.34, up from $1.05 in Q4 2024[23] - Adjusted diluted EPS guidance for fiscal 2026 is projected to be between $12.35 and $12.65[13] - Adjusted diluted EPS for FY 2026 is projected to be between $12.35 and $12.65, reflecting a reported percentage change of +4.7% to +7.2%[41] Strategic Initiatives - The combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close today, marking a significant strategic milestone[4] - BD announced a $110 million investment to support the U.S. pharmaceutical supply chain for biologic drugs, establishing production of prefillable syringes[5] - The company plans to reorganize its segments into five distinct units effective October 1, 2025, to better align with its product and service offerings[32] Segment Performance - The BioPharma Systems segment reported a 45.0% revenue increase to $150 million compared to $104 million in Q4 2024[26] - The Life Sciences segment reported revenues of $766 million, down 8.3% from $836 million in the prior year[35] - The BioPharma Systems segment generated $429 million in revenue, a 2.7% increase from $418 million in 2024[32] - The Connected Care segment's total revenue was $1,131 million, up 5.5% from $1,073 million in the previous year[32] - The Interventional segment reported total revenues of $1,330 million, a 5.8% increase from $1,257 million in 2024[32] Regulatory and Market Environment - The company is facing potential impacts from regulatory changes and market pressures, including pricing and reimbursement policies[22] - The company expects low single-digit revenue growth for FY 2026, with an illustrative foreign currency impact of approximately +120 basis points[39]

FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered strongerthanexpected firstquarter performance which reflects our disciplined execution, including accelerated commercial initiatives and broadbased growth across key end markets," said Tom Polen, chairman, CEO and president of BD. "Today, we expect to complete the ...

Becton Dickinson and Company (NYSE:BDX) will release earnings for its first quarter before the opening bell on Monday, Feb. 9.Analysts expect the company to report quarterly earnings of $2.81 per share. That’s down from $3.43 per share in the year-ago period. The consensus estimate for Becton Dickinson's quarterly revenue is $5.15 billion (it reported $5.17 billion last year), according to Benzinga Pro.According to recent news, Becton Dickinson announced on Jan. 27 a buyback plan of up to 10 million shares. ...

分组1 - Becton Dickinson is set to release its first-quarter earnings on February 9, with expected earnings of $2.81 per share, down from $3.43 per share in the same period last year [1] - The consensus estimate for Becton Dickinson's quarterly revenue is $5.15 billion, slightly lower than the $5.17 billion reported last year [1] - The company announced a buyback plan of up to 10 million shares on January 27, which has attracted investor interest in its dividends [2] 分组2 - Becton Dickinson currently has an annual dividend yield of 2.03%, with a quarterly dividend of $1.05 per share, totaling $4.20 annually [2] - To earn $500 monthly from dividends, an investment of approximately $295,103 or around 1,429 shares is required, while $100 monthly would need about $59,062 or 286 shares [2] - The dividend yield can fluctuate based on changes in the stock price and dividend payments, impacting the overall yield [3][5]

Market Overview - The Surgical Staplers Market was valued at USD 6.41 billion in 2025 and is projected to reach USD 10.87 billion by 2033, growing at a CAGR of 6.87% during the forecast period 2026-2033 [1][20] - The U.S. Surgical Staplers Market is valued at USD 2.03 billion in 2025 and is projected to reach USD 3.19 billion by 2033, growing at a CAGR of 5.82% [4][20] Growth Drivers - The global burden of chronic diseases requiring surgical intervention, rising surgical procedure volumes, and the growing acceptance of minimally invasive surgeries are driving market growth [1] - Over 310 million major surgical procedures are performed globally each year, with a significant portion being minimally invasive, increasing demand for advanced stapling devices [2] - High surgical volumes, rapid adoption of robotic-assisted surgeries, and strong hospital capital expenditure are contributing to growth in the U.S. market [4] Product Segmentation - Manual Surgical Staplers held the largest market share of 58.72% in 2025, while Powered Surgical Staplers are expected to grow at the fastest CAGR of 9.62% during 2026-2033 [9] - Disposable Surgical Staplers dominated with a 63.15% share in 2025, while Reusable Surgical Staplers are projected to expand at a CAGR of 9.47% [10] - Abdominal & Pelvic Surgery accounted for the highest market share of 35.88% in 2025, with Cardiac & Thoracic Surgery anticipated to record the fastest CAGR of 9.84% [11] End-User Insights - Hospitals & Clinics held the largest share of 71.42% in 2025, while Diagnostic Centers are expected to grow at the fastest CAGR of 9.75% during 2026-2033 [12] Regional Insights - North America had the largest market share of 42.58% due to the high number of surgeries and the use of modern stapling technology [15] - The Asia Pacific region is projected to be the fastest-growing, expanding at a CAGR of 8.34% during 2026-2033, driven by rising surgical procedures and healthcare infrastructure [16] Technological Advancements - The use of powered staplers reduces variability of manual force by over 40%, improving surgeon ergonomics and surgical outcomes [5] - Recent product launches include Ethicon's ETHICON4000 Stapler and Medtronic's enhanced Signia™ Stapling System, which feature advanced technologies for improved precision and efficiency [21]

Group 1 - Becton Dickinson and Co is highlighted for its strong performance in the medical technology sector, showing resilience amid market fluctuations [1] - Stepan Company is noted for its growth in specialty chemicals, with a focus on sustainable practices and innovation driving its market position [1] - H2O America is recognized for its advancements in water treatment solutions, contributing to environmental sustainability and addressing water scarcity issues [1] Group 2 - The overall market analysis indicates a trend towards increased investment in healthcare and environmental sectors, reflecting changing consumer preferences and regulatory pressures [1] - Companies are adapting to market demands by enhancing their product offerings and focusing on sustainability, which is becoming a key differentiator in competitive landscapes [1] - The analysis suggests that ongoing technological advancements will continue to shape the future of these industries, presenting both opportunities and challenges for investors [1]

Wall Street analysts expect Becton Dickinson (BDX) to post quarterly earnings of $2.82 per share in its upcoming report, which indicates a year-over-year decline of 17.8%. Revenues are expected to be $5.15 billion, down 0.4% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.8% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earn ...

Becton, Dickinson and Company (NYSE:BDX) is included among the Dividend Growth Stocks: 25 Aristocrats. Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX) On January 28, Piper Sandler analyst Jason Bednar lifted Becton, Dickinson and Company (NYSE:BDX)’s price recommendation to $205 from $190. The analyst maintained a Neutral rating. The firm pointed to changes in how BD reports its business units starting in Q1 2026 and said it is updating its financial model to align with the ...

Core Insights - Becton, Dickinson and Company (BDX) has successfully completed a joint feasibility study on recycling polystyrene Petri dishes into high-quality manufacturing feedstock, in collaboration with Envetec Sustainable Technologies [1][8] - The pilot study indicates that several polymers, including polystyrene, can be reintroduced into the manufacturing supply chain after effective disinfection and processing [1][4] Company Initiatives - The pilot project is part of BD's Sustainable Medical Technologies Institute and aims to develop circular economy solutions for single-use plastic medical devices, addressing long-term environmental concerns [2][4] - The initiative supports BD's strategic objective of reducing reliance on virgin plastics and lowering waste-management costs over time, positioning the company as an innovator in sustainable healthcare solutions [5][11] Market Performance - Following the announcement, BDX shares gained 1.2%, with a 13.8% increase over the past six months, compared to the industry's 15.7% growth and the S&P 500's 12.3% rise [3] Technological Advancements - The pilot utilized Envetec's GENERATIONS technology, which disinfects waste into clean, recyclable polymer flakes, demonstrating that recycled materials can meet performance standards for new products [9][10] Industry Trends - The sustainable laboratory plasticware market is projected to reach $970.97 million by 2026, with a CAGR of 19.2% through 2035, driven by increasing demand for recyclable and biodegradable products [12]

Core Insights - The article discusses the 25 best dividend aristocrat stocks, which are companies that have consistently raised their dividends for at least 25 years, appealing to investors due to their reliability in dividend growth [1] Group 1: Dividend Aristocrats Overview - Dividend aristocrats are typically mature companies with stable earnings, and management prioritizes dividend increases as a core responsibility [2] - Despite their reputation, dividend aristocrats can still reduce dividends, as evidenced by Walgreens Boots Alliance's significant cut in early 2024, highlighting that historical performance does not guarantee future safety [3] Group 2: Importance of Dividends - Research from S&P Dow Jones Indices indicates that dividends have contributed approximately 31% to the total return of the S&P 500 since 1926, with capital appreciation accounting for 69% [5] - The S&P 500 Dividend Aristocrats have historically provided higher returns with lower volatility compared to the broader S&P 500, leading to stronger risk-adjusted returns [6] Group 3: Methodology for Stock Selection - The article's methodology involved scanning a list of Dividend Aristocrats to identify companies with the strongest dividend growth rates over the past five years, resulting in a selection of 25 companies ranked by their growth rates [8] Group 4: Company Highlights - **Eversource Energy (NYSE:ES)**: - 5-Year Average Dividend Growth Rate: 5.81% - The company serves approximately 4.6 million customers and is focused on regulated utility operations, with plans to invest about $24.2 billion from 2025 to 2029 for infrastructure modernization [10][12] - Recently raised its quarterly dividend by 4.7% to $0.7875 per share, marking 26 consecutive years of dividend growth [13] - **Becton, Dickinson and Company (NYSE:BDX)**: - 5-Year Average Dividend Growth Rate: 5.97% - Announced a $110 million investment to expand production of prefillable syringes, expected to create around 120 new jobs [15][16] - Remains a leading medical technology company focused on healthcare advancements [17] - **General Dynamics Corporation (NYSE:GD)**: - 5-Year Average Dividend Growth Rate: 6.40% - Reported fourth-quarter results exceeding estimates, driven by strength in combat and marine systems, although full-year profit outlook was below expectations [19][22] - The company is experiencing strong demand across its business segments, particularly in defense, amid ongoing geopolitical tensions [21]